The global elastography imaging market is experiencing significant growth, with projections indicating that the industry will ...

Scottish Medicines Consortium Accepts Kite CAR T-Cell Therapy for Earlier Use to Treat Aggressive Blood Cancers - First SMC acceptance of any CAR T-cell therapy for lymphoma patients in the ...

New innovation drive set to inspire nurses, midwives, and AHPs to help improve NHS ScotlandFormal NHS Scotland partner InnoScot Health is launching a fresh innovation push with the aim of inspiring ...

Vienna, Austria – November 11th, 2024 – UpNano GmbH (Vienna, Austria), a leader in high-performance 2-photon polymerization (2PP) 3D printing solutions, has announced the release of the NanoOne green, ...

SAN FRANCISCO, CA / ACCESSWIRE / November 11, 2024 / Ambience Healthcare - the leading clinical AI platform for scribing, point-of-care CDI & coding, patient summaries, and referrals - today announced ...

Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable diseaseColon ...

SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump ...

STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it presented promising data from its ...

Theramex has announced that the Scottish Medicine Consortium (SMC) has recommended Yselty® for the treatment of moderate to severe symptoms of uterine fibroids (UFs) aligned to the product indication ...

The global hepatitis B diagnostic tests market is on the cusp of substantial expansion, driven by a combination of increasing disease incidence, heightened global awareness campaigns, and rapid ...

In accordance with the resolution of the Annual General Meeting on May 14th, 2024, the Chairman of the Board has contacted the company’s two largest shareholders or group of shareholders in terms of ...

TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, ...